Metronomic chemotherapy with toceranib phosphate for a disseminated histiocytic sarcoma in a miniature schnauzer dog

Hwaran Hong, Seula Lim, Hye Ri Shin, Ho Jung Choi, Haebum Lee, Kun Ho Song, Kyoung Won Seo

Research output: Contribution to journalArticle

Abstract

A 15-year-old spayed female Miniature Schnauzer was presented for unilateral foreleg lameness and pain. On physical examination, left elbow joint swelling and stiffness were identified. On a computed tomography (CT) scan, a periosteal reaction of the left humerus from the distal metaphysis to the epiphysis and cortical destruction of the medial condyle was observed. Based on blood tests, histopathology, and immunohistochemistry, it was concluded as a skeletal histiocytic sarcoma. Since the patient’s pain was not controlled despite application of a fentanyl patch, a left forelimb amputation was decided upon as part of the palliative therapy. Metronomic chemotherapy with toceranib phosphate and pamidronate was initiated. Toceranib was administered for 3 months without the development of any adverse effects except mild neutropenia. However, 3 months after initiating treatment, the toceranib was discontinued due to moderate gastrointestinal disturbances. Over the next 2 months, a left mandibular bone mass and cortical bone destruction in the bilateral tibia and tarsal joint were identified on CT. The patient became unwilling to eat and was noted to have severe skeletal pain. The anorexia and lethargy were progressively worsening and the owner decided to euthanize the patient. A necropsy was performed and the patient was definitively diagnosed with disseminated histiocytic sarcoma based on histopathologic and immunohistochemical analyses. This report describes a Miniature Schnauzer dog with DHS managed with surgical removal and metronomic chemotherapy with toceranib that survived with an improved quality of life for 7 months.

Original languageEnglish (US)
Pages (from-to)441-444
Number of pages4
JournalJournal of Veterinary Clinics
Volume34
Issue number6
DOIs
StatePublished - Dec 1 2017
Externally publishedYes

Fingerprint

Histiocytic Sarcoma
sarcoma
drug therapy
Dogs
phosphates
pain
Drug Therapy
pamidronate
dogs
computed tomography
Pain
Tarsal Joints
Tomography
bones
Bone and Bones
epiphyses
Elbow Joint
fentanyl
neutropenia
Lethargy

Keywords

  • Disseminated histiocytic sarcoma
  • Metronomic chemotherapy
  • Toceranib phosphate
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Metronomic chemotherapy with toceranib phosphate for a disseminated histiocytic sarcoma in a miniature schnauzer dog. / Hong, Hwaran; Lim, Seula; Shin, Hye Ri; Choi, Ho Jung; Lee, Haebum; Song, Kun Ho; Seo, Kyoung Won.

In: Journal of Veterinary Clinics, Vol. 34, No. 6, 01.12.2017, p. 441-444.

Research output: Contribution to journalArticle

Hong, Hwaran ; Lim, Seula ; Shin, Hye Ri ; Choi, Ho Jung ; Lee, Haebum ; Song, Kun Ho ; Seo, Kyoung Won. / Metronomic chemotherapy with toceranib phosphate for a disseminated histiocytic sarcoma in a miniature schnauzer dog. In: Journal of Veterinary Clinics. 2017 ; Vol. 34, No. 6. pp. 441-444.
@article{72e400dde65a4d789230670e3efb0f71,
title = "Metronomic chemotherapy with toceranib phosphate for a disseminated histiocytic sarcoma in a miniature schnauzer dog",
abstract = "A 15-year-old spayed female Miniature Schnauzer was presented for unilateral foreleg lameness and pain. On physical examination, left elbow joint swelling and stiffness were identified. On a computed tomography (CT) scan, a periosteal reaction of the left humerus from the distal metaphysis to the epiphysis and cortical destruction of the medial condyle was observed. Based on blood tests, histopathology, and immunohistochemistry, it was concluded as a skeletal histiocytic sarcoma. Since the patient’s pain was not controlled despite application of a fentanyl patch, a left forelimb amputation was decided upon as part of the palliative therapy. Metronomic chemotherapy with toceranib phosphate and pamidronate was initiated. Toceranib was administered for 3 months without the development of any adverse effects except mild neutropenia. However, 3 months after initiating treatment, the toceranib was discontinued due to moderate gastrointestinal disturbances. Over the next 2 months, a left mandibular bone mass and cortical bone destruction in the bilateral tibia and tarsal joint were identified on CT. The patient became unwilling to eat and was noted to have severe skeletal pain. The anorexia and lethargy were progressively worsening and the owner decided to euthanize the patient. A necropsy was performed and the patient was definitively diagnosed with disseminated histiocytic sarcoma based on histopathologic and immunohistochemical analyses. This report describes a Miniature Schnauzer dog with DHS managed with surgical removal and metronomic chemotherapy with toceranib that survived with an improved quality of life for 7 months.",
keywords = "Disseminated histiocytic sarcoma, Metronomic chemotherapy, Toceranib phosphate, Tyrosine kinase inhibitor",
author = "Hwaran Hong and Seula Lim and Shin, {Hye Ri} and Choi, {Ho Jung} and Haebum Lee and Song, {Kun Ho} and Seo, {Kyoung Won}",
year = "2017",
month = "12",
day = "1",
doi = "10.17555/jvc.2017.12.34.6.441",
language = "English (US)",
volume = "34",
pages = "441--444",
journal = "Journal of Veterinary Clinics",
issn = "1598-298X",
publisher = "Korean Society of Veterinary Clinics",
number = "6",

}

TY - JOUR

T1 - Metronomic chemotherapy with toceranib phosphate for a disseminated histiocytic sarcoma in a miniature schnauzer dog

AU - Hong, Hwaran

AU - Lim, Seula

AU - Shin, Hye Ri

AU - Choi, Ho Jung

AU - Lee, Haebum

AU - Song, Kun Ho

AU - Seo, Kyoung Won

PY - 2017/12/1

Y1 - 2017/12/1

N2 - A 15-year-old spayed female Miniature Schnauzer was presented for unilateral foreleg lameness and pain. On physical examination, left elbow joint swelling and stiffness were identified. On a computed tomography (CT) scan, a periosteal reaction of the left humerus from the distal metaphysis to the epiphysis and cortical destruction of the medial condyle was observed. Based on blood tests, histopathology, and immunohistochemistry, it was concluded as a skeletal histiocytic sarcoma. Since the patient’s pain was not controlled despite application of a fentanyl patch, a left forelimb amputation was decided upon as part of the palliative therapy. Metronomic chemotherapy with toceranib phosphate and pamidronate was initiated. Toceranib was administered for 3 months without the development of any adverse effects except mild neutropenia. However, 3 months after initiating treatment, the toceranib was discontinued due to moderate gastrointestinal disturbances. Over the next 2 months, a left mandibular bone mass and cortical bone destruction in the bilateral tibia and tarsal joint were identified on CT. The patient became unwilling to eat and was noted to have severe skeletal pain. The anorexia and lethargy were progressively worsening and the owner decided to euthanize the patient. A necropsy was performed and the patient was definitively diagnosed with disseminated histiocytic sarcoma based on histopathologic and immunohistochemical analyses. This report describes a Miniature Schnauzer dog with DHS managed with surgical removal and metronomic chemotherapy with toceranib that survived with an improved quality of life for 7 months.

AB - A 15-year-old spayed female Miniature Schnauzer was presented for unilateral foreleg lameness and pain. On physical examination, left elbow joint swelling and stiffness were identified. On a computed tomography (CT) scan, a periosteal reaction of the left humerus from the distal metaphysis to the epiphysis and cortical destruction of the medial condyle was observed. Based on blood tests, histopathology, and immunohistochemistry, it was concluded as a skeletal histiocytic sarcoma. Since the patient’s pain was not controlled despite application of a fentanyl patch, a left forelimb amputation was decided upon as part of the palliative therapy. Metronomic chemotherapy with toceranib phosphate and pamidronate was initiated. Toceranib was administered for 3 months without the development of any adverse effects except mild neutropenia. However, 3 months after initiating treatment, the toceranib was discontinued due to moderate gastrointestinal disturbances. Over the next 2 months, a left mandibular bone mass and cortical bone destruction in the bilateral tibia and tarsal joint were identified on CT. The patient became unwilling to eat and was noted to have severe skeletal pain. The anorexia and lethargy were progressively worsening and the owner decided to euthanize the patient. A necropsy was performed and the patient was definitively diagnosed with disseminated histiocytic sarcoma based on histopathologic and immunohistochemical analyses. This report describes a Miniature Schnauzer dog with DHS managed with surgical removal and metronomic chemotherapy with toceranib that survived with an improved quality of life for 7 months.

KW - Disseminated histiocytic sarcoma

KW - Metronomic chemotherapy

KW - Toceranib phosphate

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85044453300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044453300&partnerID=8YFLogxK

U2 - 10.17555/jvc.2017.12.34.6.441

DO - 10.17555/jvc.2017.12.34.6.441

M3 - Article

AN - SCOPUS:85044453300

VL - 34

SP - 441

EP - 444

JO - Journal of Veterinary Clinics

JF - Journal of Veterinary Clinics

SN - 1598-298X

IS - 6

ER -